Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial

Nom du journal : Lancet Respir Med

Année : 2018

Volume : 6

Page de départ : 431

Page de fin : 441

Auteurs: Lindner LH, Sufliarsky J, Stacchiotti S, Gelderblom H, Rutkowski P, Wozniak A, Debiec-Rychter M, Italiano A, Isambert N, Sciot R, Blay JY, Schöffski P, Strauss SJ, Leahy MG, Van Cann T, Marreaud S, Nzokirantevye A, Collette S,